Sunday, April 21, 2013

From NEJM: Risk, Consent, and SUPPORT

http://www.ncbi.nlm.nih.gov/pubmed/23597408


 2013 Apr 18. [Epub ahead of print]

Risk, Consent, and SUPPORT.

Source

From the Center for Biomedical Ethics, Stanford University, Stanford, CA (D.M.); and the Division of Medical Ethics, New York University Langone Medical Center, New York (A.L.C.).

Abstract

Comparative effectiveness research has the potential to dramatically improve patient care while reducing costs. In the absence of good evidence about which treatment is best for particular patients, decision making too often hinges on exogenous factors such as advertising and detailing by pharmaceutical companies, what a physician first learned to do, insurance coverage, and local custom. Without good evidence about what is best among competing but generally accepted clinical options, it is often a challenge for physicians to identify the best course of care. 

No comments:

Post a Comment